Personalized dosing for kids with dystonia? new study investigates genetic factors

NCT ID NCT06554288

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study is testing how the drug trihexyphenidyl is processed in the bodies of 40 children aged 5-17 with dystonic cerebral palsy. Researchers want to see if a child's genetic makeup changes how the drug works, which could help create personalized dosing plans. Participants will take the drug for 15 weeks, and the study will measure drug levels, side effects, and how well dystonia symptoms are controlled.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
trihexyphenidyl
What this could lead to
If successful, this could lead to personalized dosing guidelines for trihexyphenidyl in children with dystonia, improving treatment effectiveness and safety.
What could go wrong
This is an early Phase 1 study with only 40 participants, so results may not apply to all children. The focus is on understanding drug metabolism, not on proving the drug works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CEREBRAL PALSY, DYSKINETIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Children's Mercy Hospital Kansas City

    RECRUITING

    Kansas City, Missouri, 64108, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.